Literature DB >> 15802185

Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid beta-peptide (1-42) into rat brain: implications for Alzheimer's disease.

D Boyd-Kimball1, R Sultana, H Fai Poon, B C Lynn, F Casamenti, G Pepeu, J B Klein, D A Butterfield.   

Abstract

Protein oxidation has been shown to result in loss of protein function. There is increasing evidence that protein oxidation plays a role in the pathogenesis of Alzheimer's disease (AD). Amyloid beta-peptide (1-42) [Abeta(1-42)] has been implicated as a mediator of oxidative stress in AD. Additionally, Abeta(1-42) has been shown to induce cholinergic dysfunction when injected into rat brain, a finding consistent with cholinergic deficits documented in AD. In this study, we used proteomic techniques to examine the regional in vivo protein oxidation induced by Abeta(1-42) injected into the nucleus basalis magnocellularis (NBM) of rat brain compared with saline-injected control at 7 days post-injection. In the cortex, we identified glutamine synthetase and tubulin beta chain 15/alpha, while, in the NBM, we identified 14-3-3 zeta and chaperonin 60 (HSP60) as significantly oxidized. Extensive oxidation was detected in the hippocampus where we identified 14-3-3 zeta, beta-synuclein, pyruvate dehydrogenase, glyceraldehyde-3-phosphate dehydrogenase, and phosphoglycerate mutase 1. The results of this study suggest that a single injection of Abeta(1-42) into NBM can have profound effects elsewhere in the brain. The results further suggest that Abeta(1-42)-induced oxidative stress in rat brain mirrors some of those proteins oxidized in AD brain and leads to oxidized proteins, which when inserted into their respective biochemical pathways yields insight into brain dysfunction that can lead to neurodegeneration in AD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15802185     DOI: 10.1016/j.neuroscience.2004.12.022

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  45 in total

1.  Prevention of neurodegenerative damage to the brain in rats in experimental Alzheimer's disease by adaptation to hypoxia.

Authors:  E B Manukhina; A V Goryacheva; I V Barskov; I V Viktorov; A A Guseva; M G Pshennikova; I P Khomenko; S Yu Mashina; D A Pokidyshev; I Yu Malyshev
Journal:  Neurosci Behav Physiol       Date:  2010-07-16

2.  Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: implications for Aβ accumulation in AD brain.

Authors:  Joshua B Owen; Rukhsana Sultana; Christopher D Aluise; Michelle A Erickson; Tulin O Price; Guojun Bu; William A Banks; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2010-10-07       Impact factor: 7.376

Review 3.  Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease.

Authors:  D Allan Butterfield; Miranda L Bader Lange; Rukhsana Sultana
Journal:  Biochim Biophys Acta       Date:  2010-02-20

Review 4.  Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies.

Authors:  Aaron M Swomley; Sarah Förster; Jierel T Keeney; Judy Triplett; Zhaoshu Zhang; Rukhsana Sultana; D Allan Butterfield
Journal:  Biochim Biophys Acta       Date:  2013-10-09

Review 5.  Redox proteomics and amyloid β-peptide: insights into Alzheimer disease.

Authors:  D Allan Butterfield; Debra Boyd-Kimball
Journal:  J Neurochem       Date:  2018-11-27       Impact factor: 5.372

6.  Protein carbonylation.

Authors:  Yuichiro J Suzuki; Marina Carini; D Allan Butterfield
Journal:  Antioxid Redox Signal       Date:  2010-03       Impact factor: 8.401

Review 7.  Redox proteomics in some age-related neurodegenerative disorders or models thereof.

Authors:  D Allan Butterfield; Hafiz Mohmmad Abdul; Shelley Newman; Tanea Reed
Journal:  NeuroRx       Date:  2006-07

8.  Gene expression of glutamate metabolizing enzymes in the hippocampal formation in human temporal lobe epilepsy.

Authors:  Tore Eid; Tih-Shih W Lee; Yue Wang; Edgar Perez; Edgar Peréz; Jana Drummond; Fredrik Lauritzen; Linda H Bergersen; James H Meador-Woodruff; Dennis D Spencer; Nihal C de Lanerolle; Robert E McCullumsmith
Journal:  Epilepsia       Date:  2012-11-13       Impact factor: 5.864

9.  Proteomics-determined differences in the concanavalin-A-fractionated proteome of hippocampus and inferior parietal lobule in subjects with Alzheimer's disease and mild cognitive impairment: implications for progression of AD.

Authors:  Joshua B Owen; Fabio Di Domenico; Rukhsana Sultana; Marzia Perluigi; Chiara Cini; William M Pierce; D Allan Butterfield
Journal:  J Proteome Res       Date:  2009-02       Impact factor: 4.466

10.  Decreased levels of PSD95 and two associated proteins and increased levels of BCl2 and caspase 3 in hippocampus from subjects with amnestic mild cognitive impairment: Insights into their potential roles for loss of synapses and memory, accumulation of Abeta, and neurodegeneration in a prodromal stage of Alzheimer's disease.

Authors:  Rukhsana Sultana; William A Banks; D Allan Butterfield
Journal:  J Neurosci Res       Date:  2010-02-15       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.